Evidently

The engine is the product. Evidently reads structured and unstructured content across the record, including notes, labs, imaging, faxes, scanned documents and outside records from health exchanges, and the company describes an underlying encoding of millions of medical concepts and the connections between them. Every commercial surface, summaries, drafts, chat and reporting, is generated from that layer rather than bolted onto a system of record the company already sold. This is not the moat is the dataset case: the ontology exists to make the generative product work rather than standing in for it.

The widest generative surface in this category paired with the least described oversight, which is the pattern this index has graded C before. The product drafts admit notes, discharge summaries, emergency medicine notes and payer denial appeals, answers open clinical questions conversationally inside the EHR, and generates summaries from prompts the clinician writes. No confidence signal, no routing threshold, no abstention behaviour and no described review gate was located for any of it. The custom prompt path deserves separate weight and is the reason this sits at C rather than B. When the user composes the request, no vendor side validation can cover the output, because the vendor never saw the prompt. Whatever testing exists applies to the summary types Evidently designed, not to a question a clinician invents at the bedside, and the organisation inherits an evaluation burden that is nowhere disclosed. Ask which outputs have been validated, whether custom prompt output is treated differently from standard summaries, and what governance the organisation is expected to run on prompts its own clinicians write.

The company states a Responsible AI mission and says it provides source transparency along with training for ethical use, which is a real stated posture and more than much of this category offers. What is missing is everything that would let a buyer act on it. No model or model family is named, no accuracy figure is published, no omission or false negative measure exists, no model card or evaluation methodology was located, and the granularity of the source transparency is not described, so it is not possible to tell whether a clinician can trace an individual sentence to a source document or only see a list of documents consulted. That granularity is the whole question in this category. Ask to see it demonstrated on a long and messy chart rather than on a demo patient.

Genuinely third party measured, which is rare here, and measuring the wrong thing for the risk the product carries. KLAS Research found a 31.7 point increase in Net EHR Experience Score at University of Iowa Health Care following integration, through the Arch Collaborative, a large standardised benchmarking programme rather than a vendor survey. Allina Health reports a 6x return through risk adjustment and revenue capture. UNC Health selected the product for enterprise deployment in May 2026. An Offcall industry report ranked it the second most physician requested tool of 2025, ahead of any other chart summarisation tool, which is a demand signal rather than an outcome. A long roster of named clinicians at named institutions appear on the record with real titles, which is more accountable than the anonymous testimonial norm. Held at B because Net EHR Experience Score measures clinician satisfaction with the electronic record, not the accuracy, completeness or safety of a summary; because attributing a system wide score move to one tool is a strong causal claim from a before and after comparison with no control described; and because the return figure is vendor reported. Nothing published measures whether the summaries were correct.

No retention period, no statement on whether customer data is used to train or improve models, and no de identification posture was located. The company publishes a privacy policy and a cookie policy but no PHI specific stewardship document was retrieved. Not Rated records absent evidence rather than an assessed weakness. The scope makes the questions material: the product ingests the full record including outside records retrieved through Care Everywhere and other exchanges, so data originating at organisations other than the customer passes through it. Get retention, training use and de identification in writing.

HIPAA compliance is explicitly claimed, with the company stating the platform was built from the ground up around HIPAA and SOC 2 Type II compliance. No business associate agreement terms are published and no statement addresses whether a BAA is included, negotiated or separately priced. That is the standard middle rung on this axis: compliance asserted, instrument unpublished. The benchmark to compare it against is a vendor that publishes the BAA text itself.

SOC 2 Type II is claimed for the company itself rather than for its hosting provider or its suppliers, which puts it on the right side of the supplier certification watchlist this index maintains, and it specifies Type II rather than leaving the report type ambiguous, which answers the standing question this index asks of every SOC 2 claim. Held at B because the claim exists only as a line of marketing copy on the homepage. No trust centre, no security page, no status page and no independently checkable artifact was located, so a buyer cannot verify the report exists or read its scope without asking. Minor untidiness worth noting without weighting: the same section of the site renders the claim three different ways, and SOC 2 is an attestation rather than a certification.

No FDA clearance, device authorisation, regulatory pathway statement or clinical decision support exemption analysis was located. Not Rated reflects absent retrieval. Two capabilities make the question live rather than academic and should be raised in diligence. The product performs patient safety indicator and pediatric quality indicator review and registry abstraction, which feed regulatory and quality reporting rather than only clinician convenience. And the embedded chat answers open clinical questions at the point of care. Ask which framework the company believes governs each surface and to see the analysis written down.

The grade describes incentive structure and disclosure, and the credit belongs alongside it. Evidently states a Responsible AI mission covering source transparency and user training for ethical use, which is a considered stance rather than a slogan, and its clinician facing framing leads on wellbeing and cognitive burden. Against that, the commercial gradient is substantial and explicit. The product suite includes clinical documentation improvement review, HCC review, case mix index improvement and denial appeal drafting, the site states that side effects include better quality and reimbursement, and the flagship customer outcome is a 6x return attributed to risk adjustment and revenue capture. Risk adjustment and severity capture are among the most litigated areas of United States healthcare compliance, and drafting appeals against payer denials puts the vendor's output directly into an adversarial financial process. Case mix index makes this a second instance of documentation moving the payment unit at the admission level. Separately, no fairness, subgroup or demographic performance disclosure of any kind was located.

The right shape with a naming gap. The company states it integrates with any SMART on FHIR enabled EHR and can be customised to other systems, and an integration manager customer quote describes the fastest implementation in a 23 year career, which supports the deploy in weeks claim. Ingestion breadth is a real strength: notes, labs, imaging, faxes, scanned documents and outside records. Held at B because no EHR vendor is named in text anywhere on the site. The one system specific capability named is Care Everywhere, which is Epic's exchange, so Epic is evidently the primary target even though the marketing claims any SMART on FHIR system. An organisation outside that install base should confirm its own EHR directly rather than rely on the any EHR phrasing.

No hosting model, cloud provider, region, residency commitment or on premise option was located, and no statement describes where ingested chart data is processed or whether the customer has any choice in it. Not Rated reflects absent retrieval. This is the axis on which this category will separate, exactly as the ambient scribe lane did, and it is unanswered here.

No price, tier, mechanism or contracting model is published, and every path ends at a demo request or a contact form. Not Rated is the house convention for absent pricing rather than a low grade. The only commercial signal available is a customer reported 6x return, which describes claimed value rather than cost and should not be read as pricing transparency.

The broadest coverage in this category and it rests on instrument level work rather than on a claim of covering everything. Four distinct care settings are addressed with purpose built workflows: inpatient, outpatient value based care, emergency medicine and perioperative. Within perioperative alone it performs pre operative review, transplant review, registry abstraction and patient safety and pediatric quality indicator review, which are specific reporting instruments rather than generic summarisation, and nothing else in this category performs them. Named clinician users span pulmonology, nephrology, pediatric nephrology, pediatrics, urology, transplant surgery, infectious disease, hospital medicine and primary care, and the product is separately positioned for CDI specialists, denial specialists, population health teams, research teams, pharmacists and nurses rather than for physicians alone.